Prostate Cancer Clinical Trial
Circulating Tumor Cells in Prostate Cancer Patients
Summary
The purpose of this study is to determine if a non-invasive cancer treatment, high-dose stereotactic body radiotherapy (SBRT), is associated with changes in circulating tumor cells counts in patients with low- and intermediate-risk prostate cancer.
Full Description
SBRT (stereotactic body radiotherapy) may decrease or actually increase CTC levels in patients with cancer, and knowledge about the effects of different therapies, including SBRT, on CTC levels will be of general interest to the oncology community. Patients will undergo blood draws at defined times as indicated below.
Prior to CT-simulation, but more than 2 days after digital rectal examination
Within 24 hours following CT simulation (an endorectal balloon is used at the time of simulation)
Within 24 hours following the first treatment
Within 24 hours following the third treatment
Within 1 week following the fifth treatment
Eligibility Criteria
Inclusion Criteria:
Men who satisfy all of the following conditions will be eligible for this study:
Willing and capable to provide informed consent
Signed study specific informed consent form.
PSA ≤ 20 prior to hormone therapy (if given) for patients with Gleason 2-6. For those with Gleason score of 7. PSA should be less than or equal to 15 ng/ml prior to hormonal therapy (if given). Thus, risk of pelvic lymph node involvement according to Roach formula would be under 20%.
Gleason score ≤ 7
Appropriate staging studies identifying as AJCC stage T1a, T1b, T1c, T2a, or T2b
No direct evidence of regional or distant metastases after appropriate staging studies
Histologic confirmation of cancer by biopsy
Adenocarcinoma of the prostate
Age ≥ 18
Zubrod Performance Status 0-2
Up to 9 months of previous hormonal therapy is allowed (but not required)
AUA score must be ≤ 15 (alpha blockers allowed)
CT or Ultrasound-based volume estimation of prostate gland ≤ 60 grams
Agreement to use effective contraceptive methods such as condom/diaphragm and spermicidal foam, intrauterine device, or prescription birth control pills.
Exclusion Criteria:
Women are not eligible for this study. Men with one or more of the following conditions also are ineligible for this study:
Positive lymph nodes or metastatic disease from prostate cancer
Prior invasive malignancy unless disease free for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, or cervix, or non-melanomatous skin cancer are all permissible)
T2c, T3, or T4 tumors
Previous pelvic radiotherapy
Previous surgery or chemotherapy for prostate cancer
Previous transuretheral resection of the prostate (TURP) or cryotherapy to the prostate
Previous hormonal therapy given for more than 9 months prior to therapy
Concomitant antineoplastic therapy (including surgery, cryotherapy, conventionally fractionated radiotherapy, and chemotherapy) while on this protocol.
History of Crohn's Disease or Ulcerative Colitis.
Previous significant obstructive symptoms; AUA score must be ≤ 15 (alpha blockers allowed)
Significant psychiatric illness
Men of reproductive potential may not participate unless they agree to use an effective contraceptive method.
Ultrasound or CT estimate of prostate volume > 60 grams
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Dallas Texas, 75390, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.